The efficacy and safety of febuxostat for urate lowering in gout patients ≥65 years of age
<p>Abstract</p> <p>Background</p> <p>The incidence of gout rises with increasing age. Management of elderly (≥65 years) gout patients can be challenging due to high rates of comorbidities, such as renal impairment and cardiovascular disease, and concomitant medication u...
Main Authors: | Jackson Robert L, Hunt Barbara, MacDonald Patricia A |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2012-03-01
|
Series: | BMC Geriatrics |
Online Access: | http://www.biomedcentral.com/1471-2318/12/11 |
Similar Items
-
African American patients with gout: efficacy and safety of febuxostat vs allopurinol
by: Wells Alvin F, et al.
Published: (2012-02-01) -
Febuxostat as an effective drug of choice for urate-lowering therapy for gout (case report)
by: A. B. Bashkova, et al.
Published: (2022-08-01) -
The place of febuxostat in the treatment of gout
by: A. M. Novikova, et al.
Published: (2020-09-01) -
Efficacy and safety of febuxostat extended release and immediate release in patients with gout and moderate renal impairment: phase II placebo-controlled study
by: Lhanoo Gunawardhana, et al.
Published: (2018-05-01) -
Cardiovascular safety of febuxostat and allopurinol in patients with gout: A meta-analysis
by: Xudong Guan, et al.
Published: (2022-09-01)